Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

Active — Not RecruitingPhase 2

NCT03607890

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) s…

United States38 participantsStarted 2018-11-16

Treatment: Nivolumab, Relatlimab